NCT07232368Completed
The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
This study aims to investigate the effects of slow-paced breathing (SPB) intervention applied to patients with pulmonary arterial hypertension (PAH) in the home environment on symptom management (dyspnea, fatigue, sleep quality), clinical parameters (Six-Minute Walking Test-6MWT), IL-6, NT-proBNP results) and quality of life.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 13 Nov 2025
- Start date
- 11 Jun 2023
- Primary completion date
- 15 Sept 2023
- Lead sponsor
- Ege University
- NCT number
- NCT07232368
What you commit to
- Study type: Interventional
- Participants enrolled: 42
- From 11 Jun 2023 to the primary completion date, 15 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving a lung transplant
Other illness
- Presence of another underlying condition that may cause dyspnea, fatigue, and sleep difficulties (chronic fatigue syndrome, obstructive sleep apnea, restless legs syndrome, narcolepsy, major depression, etc.)
- Active participation in a cardiac rehabilitation program
- Presence of pulmonary hypertension due to left heart disease and pulmonary hypertension due to lung diseases and/or hypoxia
- Having had cardiac surgery within the last six months
Other
- Communication difficulties
- Symptomatic hypotension
- Pregnancy status for female participants (positive urine pregnancy test\*)
- Hospitalization or acute phase
- Presence of obesity
- Presence of mental retardation
Who the study is looking for
- Being between 18 and 65 years of age
- Being diagnosed with PAH (pulmonary arterial hypertension)- (Group I pulmonary hypertension (idiopathic, hereditary, drug or toxin-induced, or associated with connective tissue disease, congenital heart disease, or HIV-associated)) diagnosed by right heart catheterization
- Being on stable PAH treatment for the past three months and in a stable clinical condition (no changes in PAH medical treatment, no new medications added)
- Being in class II or III according to the World Health Organization functional classification
- Being able to speak Turkish
- Having a high level of technical digital literacy (obtaining the highest score (30 points) on the "technical subscale" of the Digital Literacy Scale\*)
- Agreeing to participate in the study
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ege Üniversitesi Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.